Global Idiopathic Intracranial Hypertension Treatment Market Forecasted to Grow Steadily at 6.4% CAGR Between 2025 and 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Predicted Market Size and CAGR of the Idiopathic Intracranial Hypertension Treatment Market by the End of the 2029?
The idiopathic intracranial hypertension treatment market size has grown strongly in recent years. It will grow from $1.38 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing prevalence of obesity, increasing healthcare expenditure, growing focus on minimally invasive surgical procedures, rising prevalence of comorbid conditions, and rising demand for improved ophthalmologic diagnostic tools.
The idiopathic intracranial hypertension treatment market size is expected to see strong growth in the next few years. It will grow to " $1.89 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to rise in the adoption of digital health solutions, rise in lifestyle disorders, an increasing use of telemedicine, increasing availability of advanced diagnostic tools, and increasing demand for personalized medicine. Major trends in the forecast period include the adoption of AI-driven diagnostic tools, development of targeted therapies, advancements in non-invasive imaging techniques, the introduction of new weight management drugs, and the development of customizable shunt devices.
Get your free report sample today:
Which Factors Are Contributing Most to the Expansion of the Idiopathic Intracranial Hypertension Treatment Market?
The increasing prevalence of obesity is expected to propel the growth of the idiopathic intracranial hypertension treatment market going forward. Obesity refers to a medical condition where a person has excessive body fat that may harm their health. Obesity is rising due to increasingly sedentary lifestyles combined with a surge in the consumption of calorie-dense processed foods. Obesity increases intracranial pressure by promoting excessive cerebrospinal fluid production and impairing its absorption, contributing to idiopathic intracranial hypertension. For instance, in 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department responsible for maintaining public health policies, between 2022 and 2023, 64.0% of adults aged 18 and over in England were classified as overweight or living with obesity. This figure is similar to the 63.8% reported during the 2021 to 2022 period. Therefore, the increasing prevalence of obesity is driving the growth of the idiopathic intracranial hypertension treatment market.
Which Key Segments Are Included in the Idiopathic Intracranial Hypertension Treatment Market Analysis?
The idiopathic intracranial hypertension treatmentmarket covered in this report is segmented –
1) By Treatment Type: Medications; Surgeries; Therapies
2) By Treatment Administration: Oral Administration; Intrathecal Administration
3) By Diagnostic Type: Neuroimaging; Lumbar Puncture; Visual Field Tests
4) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centres
Subsegments:
1) By Medications: Diuretics; Corticosteroids; Acetazolamide
2) By Surgeries: Shunt Surgery; Optic Nerve Sheath Fenestration; Stenting
3) By Therapies: Weight Management Programs; Lifestyle Modifications; Physical Therapy
What Are the Most Prominent Trends Impacting the Idiopathic Intracranial Hypertension Treatment Market?
Major companies operating in the idiopathic intracranial hypertension treatment market are focusing on developing innovative therapies to manage intracranial pressure and associated symptoms. These therapies aim to improve patient outcomes by utilizing advanced drug delivery systems and targeted treatment approaches, enhancing overall care and quality of life. For instance, in November 2022, Invex Therapeutics, an Australia-based biopharmaceutical company, received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to commence the Phase III IIH EVOLVE clinical trial for Presendin (sustained-release exenatide) to treat idiopathic intracranial hypertension (IIH). The approval, along with clearance from the New Zealand Health and Disability Ethics Committee, will enable Invex to conduct the trial involving 240 newly diagnosed IIH patients across up to 40 global clinical sites, focusing on improving treatment outcomes for this neurological condition.
Who Are the Top Industry Players Driving the Idiopathic Intracranial Hypertension Treatment Market Growth?
Major companies operating in the idiopathic intracranial hypertension treatment market are Siemens AG, Medtronic plc, Mayo Clinic, Becton Dickinson and Company, Philips Healthcare, GE HealthCare Technologies Inc., Teva Pharmaceuticals, Boston Scientific Corporation, Henry schein, Sun Pharmaceutical Industries, Zydus LifeSciences, Topcon Corporation, Natus Medical Incorporated, Canon Medical Systems Corporation, Carl Zeiss Meditec AG, Optopol Technology, Strides Pharma, NIDEK Co., Haag-Streit AG, Invex Therapeutics, Metrovision.
Get the detailed idiopathic intracranial hypertension treatment market report today
Which Regional Markets Offer the Most Promising Growth Opportunities for the Idiopathic Intracranial Hypertension Treatment Market?
North America was the largest region in the idiopathic intracranial hypertension treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic intracranial hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment